Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07855419
Starting soon Observational

Sarcopenia and Interlaminar Epidural Steroid Injection Outcomes in Lumbar Spinal Stenosis

NCT07855419 · tracked via the Priya Life Science Turkey tracker
Sponsor
Marmara University
Phase
Observational
Started
2026-10
Last updated
2026-10-02

Condition(s) studied

Spinal Stenosis LumbarSarcopenia

Study summary

This prospective observational study aims to investigate the association between sarcopenia and clinical outcomes following interlaminar epidural steroid injection in patients with lumbar spinal stenosis.

Patients who are scheduled to undergo interlaminar epidural steroid injection as part of routine clinical care will be enrolled. Before the procedure, sarcopenia-related assessments, including the SARC-F questionnaire, handgrip strength, and the five-times sit-to-stand test, will be performed. Lumbar magnetic resonance imaging (MRI) will also be evaluated for paraspinal muscle characteristics and the severity of lumbar spinal stenosis.

Pain intensity, functional status, walking capacity, and health-related quality of life will be assessed at baseline. Pain intensity, functional status, and health-related quality of life will be reassessed at 3 weeks and 3 months after the procedure. The study will evaluate whether sarcopenia and MRI-based paraspinal muscle characteristics are associated with clinical outcomes following interlaminar epidural steroid injection.

Eligibility

Sex
ALL
Min age
50 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Clinical and radiological diagnosis of lumbar spinal stenosis * Persistent symptoms despite conservative treatment and scheduled to undergo interlaminar epidural steroid injection as part of routine clinical care * Age between 50 and 75 years * Low back and/or leg pain for at least 3 months * Availability of lumbar magnetic resonance imaging (MRI) Exclusion Criteria: * History of lumbar fusion surgery * Lumbar epidural steroid injection within the previous 3 months * Prominent radiculopathy due to lumbar disc herniation * Severe motor deficit or an indication for surgical treatment * Polyneuropathy, neuromuscular disease, or neurological disease that may significantly affect muscle mass * Active malignancy or systemic inflammatory disease * Significant mobility limitation due to advanced hip or knee osteoarthritis * Cognitive impairment or communication problems that may prevent completion of study assessments * Coagulopathy or active infection constituting a contraindication to epidural injection * Inflammatory rheumatic disease requiring chronic corticosteroid therapy

Primary outcome measure(s)

  • Change in Leg Pain Following Interlaminar Epidural Steroid Injection by Sarcopenia Status — Baseline, 3 weeks, and 3 months
    Leg pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. NRS scores will be recorded at baseline, 3 weeks, and 3 months. Changes in leg pain intensity from baseline will be compared between patients with and without sarcopenia.

Trial sites (1)

FacilityCityRegionStatus
Marmara University Pendik Training and Research Hospital Istanbul Istanbul

More Marmara University trials in Turkey

Investigation of Medial Longitudinal Arch and Foot Function in Patients With Lipedema Recruiting
AI-Based Prediction of Root Coverage Outcome From Intraoral Photographs Recruiting
Comparison of Intrathecal Morphine and Rectus Sheath Block for Postoperative Pain Management After Lower Abdominal Surgery With Midline Incision Active, not recruiting
The Effect of Inspiratory Exercises on Diaphragm and Intercostal Muscle Thickness in Stroke Patients Starting soon
Physicians' Perception About Patient Pain in Flexible Cystoscopy With Local Anesthesia Enrolling by invitation

Other trials for the same condition

Does Sarcopenia Influence Rotator Cuff Tear Patterns? Radiological Insights From Patients With Rotator Cuff Syndrome Recruiting
Effects of Aquatic Exercise in Older Adults With Sarcopenia:A Randomized Trial Active, not recruiting
Malnutrition Screening Study Recruiting
Examining the Effects of Different Resistive Exercise Programs in Individuals With Compensated Liver Cirrhosis Starting soon
Sarcopenia and Related Factors in Patients With Multiple Sclerosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07855419 on ClinicalTrials.gov ↗ ← All trials in Turkey